TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?Zacks Investment Research • 09/26/25
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic DeviceBusiness Wire • 09/22/25
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney DiseasePRNewsWire • 09/15/25
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac ImagingBenzinga • 09/11/25
Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA MoveInvestors Business Daily • 09/11/25
TEM Gains Validation for PurIST Amid Evolving Cancer Care LandscapeZacks Investment Research • 09/11/25
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel DeviceBusiness Wire • 09/11/25
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?Zacks Investment Research • 09/09/25
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic CancerBusiness Wire • 09/09/25
Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
After An Odd Start, Tempus AI Is Making A Beeline To The Good End Of The AI RainbowSeeking Alpha • 09/08/25
Tempus AI: Strategic AI Advancements In Precision Oncology With Solid Stock Upside PotentialSeeking Alpha • 09/08/25
Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily ScrutinizedSeeking Alpha • 09/04/25